-
2m 46s
-
6m 34s
-
2m 46sPart 3 | Session 10 Lifetime Benefit by Control of Modifiable Risk Factors
-
10m 27sPart 3 | Session 11 CardiAMP-HF: Autologous Cell Therapy in Patients With HFrEF
-
3mPart 4 | Session 1 4 Trials That Will Change My Practice with Dr Ambarish Pandey
-
4m 27sPart 4 | Session 2 4 Trials That Will Change My Practice with Dr Dipti Itchhaporia
-
30m 45sPart 1 | Session 1 View from the Thoraxcenter: What's Hot at ACC.25?
-
39m 2sPart 1 | Session 2 View from the Thoraxcenter: ACC 25 Wrap-Up
-
17m 26sPart 2 | Session 1 ADVANCE-HTN: Lorundrostat in Patients with Uncontrolled Hypertension
-
11m 44sPart 2 | Session 2 STRIDE: Semaglutide for Functional Capacity in Patients with T2D and PAD
-
12m 9sPart 2 | Session 3 API-CAT: Reduced Vs Full Dose Apixaban for Cancer-Associated Thrombosis
-
14m 1sPart 2 | Session 4 FRESH-UP: Liberal Intake Vs Fluid Restriction in Chronic Heart Failure
-
20m 59sPart 2 | Session 5 SOUL: Semaglutide in Patients with T2D
-
13m 47sPart 2 | Session 6 BHF PROTECT-TAVI: Cerebral Embolic Protection in TAVI
-
4m 15sPart 3 | Session 1 The Phase 3 REVERSE-IT Trial
-
4m 3sPart 3 | Session 2 EVOLUT Low Risk: 5Y Outcomes After TAVR or SAVR in Low-Risk Patients with AS
-
4m 14sPart 3 | Session 3 SMART-CHOICE 3: Clopidogrel vs Aspirin Monotherapy in High-Risk PCI Patients
-
9m 39s
-
2m 54s
-
4m 58sPart 3 | Session 6 MIGHTy-Heart: Mobile Integrated Health in Heart Failure
ACC 2025 - First-in-human results from MyPEAK-1 show Tn-201 treatment in adults with Mybpc3-associated hypertropic cardiomyopathy was feasible and safe.
Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at ACC 2025 to discuss phase Ib/2a results from the first-in-human, non-randomized study investigating the safety and early efficacy of Tn-201, an adeno-associated virus serotype 9 gene replacement therapy, in adults with Mybpc3-associated hypertrophic cardiomyopathy (NCT05836259; Tenaya Therapeutics). The primary outcome measures of MyPEAK-1 were the number and severity of adverse events over the course of the study and the number of serious adverse events related to the study drug.
Key findings in the first three patients showed the treatment was feasible, and safe.
Interview Questions:
1. What is Mybpc3-associated HCM and what is the prevalence?
2. What are the current unmet needs in managing Mybpc3-associated hypertrophic cardiomyopathy, and why is this trial important?
3. Could you tell us about the mechanism of action behind Tn-201?
4. What was the study design and patient population?
5. What were the key findings, and were there any surprising results?
6. How should these findings impact clinical practice?
7. What further study is needed in this area?
Recorded on-site at ACC in Chicago, 2025.
Editors: Yazmin Sadik, Jordan Rance
Videographers: Dan Brent, David Ben-Harosh
Support: This is an independent interview produced by Radcliffe Cardiology.
Keep up-to-date with our video collection on the American College of Cardiology's 74th annual congress, covering late-breaking science, featured science and clinical horizon sessions. Don't miss the preview and wrap-up of the congress in our View From the Thoraxcenter series, concise Expert Interviews with select faculty offering take-home messages for practice, and our Highlights summarising the most influential trials.
More from this programme
Faculty Biographies
Milind Y Desai
Professor of Medicine
Dr Milind Desai works as the Director of the Hypertrophic Cardiomyopathy Center at the Heart, Vascular and Thoracic Institute at Cleveland Clinic. He also serves as a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine.
Alongside holding the Haslam Family Endowed Chair in Cardiovascular Medicine, Dr Desai has dual appointments in the Departments of Cardiovascular Medicine, within the Section of Cardiovascular Imaging, and Radiology. He is also a visiting professor at the University of Oxford, UK.
Dr Desai's clinical interests are heart valve disease, hypertrophic cardiomyopathy, aortic disorders, complex coronary artery disease, pericardial disease, and radiation heart disease. Dr Desai has a special interest in multimodality cardiovascular imaging, including echocardiogram, computed tomography (CT) scan and magnetic resonance imaging (MRI).
Comments